Pharma Focus Europe

BioSyent Extends Agreement for RepaGyn® and Proktis-M®

Monday, April 15, 2024

BioSyent Inc. is excited to announce that its subsidiary, BioSyent Pharma Inc., has prolonged its Exclusive License and Distribution Agreement with its European partner for the RepaGyn® and Proktis-M® products, granting exclusive Canadian rights until 2032.

René Goehrum, President and CEO of BioSyent, expressed his satisfaction with the extension, emphasizing the importance of RepaGyn® and Proktis-M® in their product lineup since their introduction in Canada in 2014. He reiterated the company's dedication to providing these reliable products to Canadian patients for the foreseeable future, anticipating continued growth.

RepaGyn® is an innovative vaginal suppository designed to alleviate vaginal dryness and promote healing of the vaginal mucosa. It is formulated with sodium hyaluronate, offering a hormone-free treatment option clinically proven to relieve symptoms and support tissue repair. Meanwhile, Proktis-M® rectal suppositories, also containing sodium hyaluronate, aid in healing severe internal hemorrhoids, anal fissures, and radiation-induced proctitis.

Both products have earned trust among patients for their effectiveness. 



Thermo Fisher Scientific - mRNA ServicesWorld Orphan Drug Congress 2024World Vaccine Congress Europe 2024Advanced Therapies USA 2024